These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17290734)

  • 1. Prostate cancer: a practical approach to current management of recurrent disease.
    Walczak JR; Carducci MA
    Mayo Clin Proc; 2007 Feb; 82(2):243-9. PubMed ID: 17290734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective.
    Baum N; Levy J
    Postgrad Med; 2015 Aug; 127(6):654-9. PubMed ID: 26118565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy.
    Tzou K; Tan WW; Buskirk S
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):125-36. PubMed ID: 21166517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA relapse prostate cancer: the importance of tailored therapy.
    Aranha O; Vaishampayan U
    Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
    Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
    N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for localized, high-risk prostate cancer.
    Narayan S; Smith DC; Sandler HM
    Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of biochemically recurrent prostate cancer following local therapy.
    Kolodziej M
    Am J Manag Care; 2014 Dec; 20(12 Suppl):S273-81. PubMed ID: 25734963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.
    Boorjian SA; Tollefson MK; Thompson RH; Rangel LJ; Bergstralh EJ; Karnes RJ
    J Urol; 2012 Nov; 188(5):1761-6. PubMed ID: 22998913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
    Sandler HM; Eisenberger MA
    J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.